185 related articles for article (PubMed ID: 30830863)
1. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
[TBL] [Abstract][Full Text] [Related]
2. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
3. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
4. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
Nadin SB; Sottile ML; Montt-Guevara MM; Gauna GV; Daguerre P; Leuzzi M; Gago FE; Ibarra J; Cuello-Carrión FD; Ciocca DR; Vargas-Roig LM
Cell Stress Chaperones; 2014 Jul; 19(4):493-505. PubMed ID: 24307543
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
7. Multifactorial approach to predicting resistance to anthracyclines.
Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
[TBL] [Abstract][Full Text] [Related]
8. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
9. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
10. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein.
Chen Y; Li L; Zeng J; Wu K; Zhou J; Guo P; Zhang D; Xue Y; Liang L; Wang X; Chang LS; He D
Chemotherapy; 2012; 58(4):264-72. PubMed ID: 22986993
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
Zhang X; Su X; Guo Z; Jiang X; Li X
J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
15. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
16. Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer.
McGuirk S; Audet-Delage Y; Annis MG; Xue Y; Vernier M; Zhao K; St-Louis C; Minarrieta L; Patten DA; Morin G; Greenwood CM; Giguère V; Huang S; Siegel PM; St-Pierre J
Elife; 2021 Jun; 10():. PubMed ID: 34181531
[TBL] [Abstract][Full Text] [Related]
17. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.
Eralp Y; Derin D; Ozluk Y; Yavuz E; Guney N; Saip P; Muslumanoglu M; Igci A; Kücücük S; Dincer M; Aydiner A; Topuz E
Ann Oncol; 2008 Apr; 19(4):669-74. PubMed ID: 18006896
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
[TBL] [Abstract][Full Text] [Related]
20. Anthracyclines in the treatment of gynecologic malignancies.
Maluf FC; Spriggs D
Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
